Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Lynda Benmahammed"'
Autor:
Laurent Machet, Caroline Dutriaux, Nora Kramkimel, Laetitia Verdoni, Lionel Lattenist, Emilie Scherrer, Eve-Marie Neidhardt, Lynda Benmahammed-Bellagha, Philippe Saiag, Jean-Jacques Grob, Marie-Thérèse Leccia, Florent Grange, Anne-Bénédicte Duval-Modeste, F. Aubin, Laurent Mortier, Florence Brunet-Possenti, Caroline Robert, Axelle Spampinato, Olivier Dereure, Nicolas Meyer
Publikováno v:
Annales de Dermatologie et de Vénéréologie - FMC. 1:A338-A339
Autor:
Nicolas Meyer, Caroline Dutriaux, Evelyne Boos, Catherine Hunault, Philippe Saiag, Laurent Mortier, Lynda Benmahammed
Publikováno v:
Journal of Clinical Oncology. 36:9563-9563
9563Background: Advanced mucosal melanoma is a rare subgroup of tumors for which few data on immune therapeutic approaches is available as they are rarely or not included in pivotal trials. Pembrol...
Autor:
Abir Tadmouri, Nicolas Meyer, Laurent Mortier, Catherine Hunault, Caroline Dutriaux, Lynda Benmahammed, Philippe Saiag, Ouzna Morsli, Marie Thérèse Leccia
Publikováno v:
Journal of Clinical Oncology. 36:9555-9555
9555Background: Information on the use of radiotherapy in anti-PD-1 monoclonal antibody-treated melanoma pts is limited although some data support a synergistic effect. Methods: We investigated the...
Autor:
Marie Thérèse Leccia, Philippe Saiag, Laurent Mortier, Lynda Benmahammed, Nicolas Meyer, Brigitte Dréno, Evelyne Boos, Caroline Dutriaux, Catherine Hunault
Publikováno v:
Journal of Clinical Oncology. 36:e21519-e21519
e21519Background: Pembrolizumab (PBZ), a monoclonal anti-PD1 antibody, has been approved in France as a first-line treatment of patients with advanced melanoma in Oct. 2015. Although this treatment...
Autor:
Amir Khammari, Marie Thérèse Leccia, Abir Tadmouri, Nicolas Meyer, Lynda Benmahammed, Caroline Dutriaux, Laurent Mortier, Catherine Hunault, Philippe Saiag
Publikováno v:
Journal of Clinical Oncology. 36:e21508-e21508
e21508Background: Pembrolizumab (PBZ), a monoclonal anti-PD-1, is approved in France since Oct 2015, as a first-line treatment of patients with advanced melanoma. Although this treatment was shown ...